Association of cabozantinib dose reductions for toxicity with clinical effectiveness in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).
Jeffrey Graham(University of Calgary), Georg A. Bjarnason(Sunnybrook Health Science Centre), Han‐Bo Zhang, Aaron R. Hansen(Princess Margaret Cancer Centre), Naveen S. Basappa, Aly‐Khan A. Lalani(Juravinski Cancer Centre), Denis Soulières(Centre Hospitalier de l’Université de Montréal), Sunita Ghosh(Tata Memorial Hospital), Lori Wood(Dalhousie University), Vincent Castonguay(Centre hospitalier universitaire de Québec), Michel Pavic(University of Bologna), Christian Kollmannsberger(BC Cancer Agency), Daniel Yick Chin Heng(University of Calgary), Anil Kapoor(People’s University)
Cited by 2
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I
|European Urology|2008|617
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
|Cancer Discovery|2018|520
Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline
|The Journal of Urology|2019|482